Dimensional Fund Advisors LP Buys New Stake in Mural Oncology plc (NASDAQ:MURA)

Dimensional Fund Advisors LP bought a new stake in shares of Mural Oncology plc (NASDAQ:MURA) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 22,563 shares of the company’s stock, valued at approximately $71,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Acadian Asset Management LLC acquired a new position in shares of Mural Oncology during the 2nd quarter valued at $998,000. Nicollet Investment Management Inc. acquired a new position in shares of Mural Oncology during the 2nd quarter valued at $308,000. Harbor Capital Advisors Inc. purchased a new stake in Mural Oncology during the 2nd quarter worth $115,000. Rhumbline Advisers purchased a new stake in Mural Oncology during the 2nd quarter worth $34,000. Finally, BBR Partners LLC purchased a new stake in Mural Oncology during the 2nd quarter worth $31,000. Institutional investors and hedge funds own 80.21% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on MURA. Rodman & Renshaw began coverage on shares of Mural Oncology in a research note on Friday, June 28th. They set a “buy” rating and a $15.00 price target on the stock. Raymond James initiated coverage on shares of Mural Oncology in a research note on Friday, October 4th. They set a “strong-buy” rating and a $18.00 price target on the stock.

Mural Oncology Price Performance

NASDAQ MURA opened at $3.45 on Wednesday. The company’s 50 day simple moving average is $3.26 and its 200 day simple moving average is $3.46. Mural Oncology plc has a 12 month low of $2.88 and a 12 month high of $17.00. The company has a market capitalization of $58.39 million and a P/E ratio of -0.33.

Mural Oncology (NASDAQ:MURA) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($1.86) EPS for the quarter, beating the consensus estimate of ($1.90) by $0.04. On average, analysts anticipate that Mural Oncology plc will post -7.47 earnings per share for the current year.

Mural Oncology Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.